Main menu

Recent Pfizer Press Releases

12/18/14 8:00am EST
Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia

Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction.

12/17/14 8:00am EST
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy

Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. PF-06252616 is an experimental, infused, anti-myostatin monoclonal antibody.

12/16/14 10:00am EST
Pfizer Invites Public To View And Listen To Webcast Of January 27 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2014 Performance Report, to be issued that morning.

12/16/14 8:00am EST
Meningococcal Meningitis Survivor and TV Personality Amy Purdy and Pfizer Launch Take Action Against Meningitis

New Campaign Encourages Parents to Take a Pledge to Talk to Their Healthcare Provider About Helping to Protect Their Teen or Young Adult from Meningococcal Meningitis

Paralympic®* medalist and world class snowboarder Amy Purdy and her mother, Sheri, have teamed up with

12/15/14 12:06pm EST
Pfizer Declares First-Quarter 2015 Dividend

Board of Directors Approves Increase in Quarterly Cash Dividend to $0.28 Per Share

The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Pfizer increased the dividend by approximately 8 percent, to 28 cents from 26 cents per share.


12/15/14 8:00am EST
OPKO and Pfizer Enter into Global Agreement for OPKO’s Long-Acting Human Growth Hormone (hGH-CTP)


hGH-CTP in global clinical development for the treatment of pediatric and adult growth hormone deficiency (GHD)
hGH-CTP has potential to reduce dosing frequency of human growth hormone to single weekly injection from current standard of daily injection
OPKO to receive upfront payment of $295 million and eligible to receive up to an additional $275 million upon achievement of regulatory milestones
Upon Pfizer’s commercialization of hGH-CTP, OPKO is eligible to receive royalty and/or profit sharing payments
Pfizer to obtain exclusive license to commercialize hGH-CTP globally 

OPKO Health, Inc. (NYSE:OPK) and Pfizer Inc. (NYSE:PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age.

12/10/14 9:00am EST
Pfizer and Brenda Strong Encourage Women to Change the Conversation on Sexual Health Post-Menopause

Light-Hearted, Informative Video Refreshes ‘The Mother, Daughter Talk’

Nearly one out of every two (45.25%) American women will be menopausal or approaching menopause next year. While most women are aware of menopausal symptoms, such as hot flashes and night sweats, fewer know about a condition that affects one-third of women called postmenopausal vaginal atrophy.

12/9/14 10:30am EST
New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers


MYLOTARG™ (gemtuzumab ozogamicin) Demonstrates Promising Efficacy Across Multiple Phase 3 Studies in First-Line Acute Myeloid Leukemia (AML)1,2

Pfizer in Discussions with Regulators on Path Forward for MYLOTARG

New Long-Term, Follow-Up Data Show Chronic Myeloid Leukemia (CML) Patients Benefit from BOSULIF® (bosutinib) at 4 and 5 years3,4

Inotuzumab Ozogamicin Shows Activity in Phase 2 Study of Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)5

Pfizer Inc. (NYSE:PFE) today announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).

12/8/14 1:30pm EST
Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

Data Presented Today at the 56th Annual American Society of Hematology (ASH) Meeting

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects.

12/8/14 8:00am EST
Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform


Signs Collaboration with Spark Therapeutics to Advance Phase 1/2 Adeno-Associated Virus (AAV) Vector Program in Hemophilia B
Launches Gene Therapy Unit Headed by Michael Linden, Ph.D., Leading Researcher from King's College London

Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.

12/2/14 8:00am EST
New Survey Finds Majority of Women with Breast Cancer Who Work Want to Do So Even While Undergoing Treatment

  • Three out of four women surveyed feel working aids in their recovery, and healthcare professionals agree
  • Greater support and communication from employers and healthcare professionals can help women with breast cancer thrive in the workplace

A new survey reveals that 77 percent of working women with breast cancer, including those with metastatic disease, feel that working aids in their recovery – a view shared almost unanimously by healthcare professionals, who were also surveyed (92%). The Supporting Workplace Conversations survey is the first to comprehensively examine the perspectives of working women with breast cancer, healthcare professionals and employers on the topic of breast cancer and the workplace.

12/1/14 7:30am EST
Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

11/17/14 8:00am EST
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)


Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants
- - - 
Data Presented Today during American Heart Association 2014 Scientific Sessions: "Clinical Science: Special Reports" Session

Portola Pharmaceuticals (NASDAQ: PTLA), Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies.

11/17/14 2:53am EST
Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology


PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC
Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015
Updates 2014 Reported Diluted EPS Range Solely to Reflect the Transaction
Analyst Call Scheduled for 10 a.m. EST on Monday, November 17, 2014

Pfizer Inc. (NYSE:PFE) announced today that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer.

11/13/14 11:01am EST
Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana® Press, for Women Most in Need in the World’s Poorest Countries

Collaboration will help advance progress and support global efforts to increase access to voluntary family planning information, services and contraceptives by 2020

11/12/14 8:00am EST
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting


21 Abstracts, Including Additional Clinical Trial Data and Real-World Analyses, Add to the Body of Evidence for XELJANZ® (Tofacitinib Citrate) as a Treatment Option for Adults with Moderate to Severe Rheumatoid Arthritis
- - - 
Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
- - - 
Phase 1 Abstracts for Two Pfizer Biosimilars in Development; Both Assets Move into Phase 3 Comparability Trials

Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts).